Oculis' Privosegtor improves visual function in Phase 2 optic neuritis trial
OCS•Oculis said its Phase 2 ACUITY trial of privosegtor in acute optic neuritis showed improved visual function, preserved retinal anatomy and reduced blood neurofilament levels. The findings supported FDA Breakthrough Therapy and European Medicines Agency PRIME designations.
1. Trial findings and next steps
Oculis said its Phase 2 ACUITY trial of privosegtor in acute optic neuritis showed improved visual function, preservation of retinal anatomy and reduced blood neurofilament levels. The company will present the results at the CNS Summit on November 2–3, 2026. Its PIONEER-1 registrational trial is enrolling patients with acute-onset optic neuritis, with or without multiple sclerosis, and Oculis expects investigational new drug application clearance for acute multiple sclerosis relapses in the fourth quarter of 2026.
